Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | UBE2M | P61081 | 2/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311246 | 0.86 | STS (0.56) | KMT2AHSD11B1UBE2MDCUN1D1MGLL | |
| SCHEMBL15732567 | 0.86 | GAA (0.50) | KMT2AHSD11B1UBE2MDCUN1D1MGLL | |
| SCHEMBL3628692 | 0.86 | KMT2A (0.49) | KMT2AHSD11B1UBE2MDCUN1D1MGLL | |
| SCHEMBL805657 | 0.85 | RXFP1 (0.51) | CCR2LMNAPOLBHPGDACKR3 | |
| SCHEMBL311460 | 0.84 | HSD11B1 (0.53) | HSD11B1MGLLCCR2 | |
| SCHEMBL15732620 | 0.82 | POLB (0.43) | KMT2AHSD11B1UBE2MDCUN1D1LMNA | |
| SCHEMBL23443582 | 0.82 | HSD11B1 (0.55) | KMT2AHSD11B1UBE2MDCUN1D1MGLL | |
| SCHEMBL15732637 | 0.81 | NOTUM (0.45) | KMT2AHSD11B1UBE2MDCUN1D1LMNA | |
| SCHEMBL18640238 | 0.78 | UBE2M (0.72) | KMT2AUBE2MDCUN1D1TSHRLMNA | |
| SCHEMBL17597825 | 0.77 | KMT2A (0.56) | KMT2AHSD11B1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | KMT2A 3302/4885HSD11B1 4245/4885UBE2M 2168/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | KMT2A 3302/4885HSD11B1 4245/4885UBE2M 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.